14 01, 2025

Protein tags, why and why not?

2025-01-14T13:00:28+00:00January 14th, 2025|animal-free, Blog, protein science, quality, Resources|

Protein tags are useful tools for affinity purification and other biochemical applications, but unnecessary tagging of proteins can cause issues. Read our latest blog and discover - Protein tags, why and why not?

14 08, 2024

ISSCR 2024: scientists and suppliers working together will improve the future of stem cell research

2024-10-10T08:22:00+00:00August 14th, 2024|animal-free, Blog, Event, News, stem cells|

Qkine is a company run by scientists, and the science is the focus of everything we do.Our theme at ISSCR this year was stress-free stem cell culture - exploring how suppliers of recombinant proteins can proactively improve the quality, availability and functionality of growth factors to generate experimental outcomes faster, easier and more efficiently.We discussed priorities for the stem cell science supply chain with scientists from academic and industry labs and had in-depth conversations about the impact of growth factors and cytokines quality on reproducibility and how to integrate new technologies, such as controlled-release and thermostable proteins, to improve the scalability of expansion and differentiation protocols.Through collaboration, we learn and, together, improve the future of stem cell research.

24 07, 2024

ISSCR 2024 reflections on “Standards for Human Stem Cell Use in Research” and growth factors for cell therapy manufacture

2024-07-25T16:45:56+00:00July 24th, 2024|animal-free, Blog, News, protein science, quality, Resources, stem cells|

Reflections on the dynamic ISSCR 2024 workshop on Standards for Human Stem Cell Use in Research including recommendations for growth factor supply chains for raw (ancillary materials) for cell therapy and ATMP manufacture.

24 07, 2024

The Cautionary Tale of GDF-15

2024-07-25T06:11:35+00:00July 24th, 2024|animal-free, Blog, News, protein science, quality, Resources|

Commercial sources of recombinant human GDF15 protein, in particular those purified from mammalian expression, are frequently contaminated with trace amounts of TGFβ and related proteins. These trace contaminants cause misleading experimental results due to the picomolar or even femtomolar EC50s of this family of cytokines.  Please be cautious with your source of recombinant GDF15 protein.

9 07, 2024

Qkine and StemCultures collaborate to provide new solutions for precision stem cell culture

2024-07-09T16:09:20+00:00July 9th, 2024|animal-free, Blog, News, Press Release, protein engineering, protein science, quality, Resources, stem cells|

Specialist bioactive growth factor protein manufacturer Qkine today announced a new partnership with StemCultures, a life sciences company dedicated to developing innovative reagents that enhance the quality and efficiency of cell growth and differentiation in culture.

20 06, 2024

Selection of growth factors and cytokines source for the manufacture of cell therapies, tissue-engineered products and translational stem cell research applications

2024-06-20T07:54:39+00:00June 20th, 2024|animal-free, Blog, News, Resources|

The manufacture of cell and gene therapy products and tissue-engineered regenerative medicine products often requires recombinant proteins such as growth factors and cytokines. These are classified as raw or ancillary materials ie. culture media components or reagents that are not intended to be included in the final product.

5 06, 2024

Transitioning to a fully animal origin-free recombinant protein manufacturing process

2024-06-10T12:23:43+00:00June 5th, 2024|animal-free, Blog, News, Resources|

We've recently fully transitioned to an animal origin-free (AOF) manufacturing process for our recombinant proteins. This shift ensures the highest standards of safety, purity, and sustainability in bioproduction. By eliminating all animal-derived components, including heparin-based purification columns, we’re supporting ethical and cruelty-free biomanufacturing. Learn more about our journey to 100% AOF.

8 10, 2021

Qkine appoints Japanese distribution partner MBL to extend global availability of its innovative stem cell and organoid culture reagents

2021-10-08T12:15:37+00:00October 8th, 2021|animal-free, News, organoid news|

Qkine has concluded a sales distribution agreement with Japanese company, MBL Medical & Biological Laboratories Co., Ltd. MBL have extensive knowledge and presence within the Japanese regenerative medicine and iPSC sector, an important market for Qkine's high purity, animal-free optimised growth factor and cytokine proteins. The two companies share a focus on product quality and the emerging areas of organoid and organ-on-chip technologies for basic research, personalised medicine and drug discovery. This distributor agreement between Qkine and MBL will facilitate access to Qkine's entire range of premium quality, animal-free and novel optimised growth factor proteins across Japan.

26 07, 2021

Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

2021-07-26T08:14:57+00:00July 26th, 2021|animal-free, cellular agriculture, News, Press Release, protein engineering, protein science, stem cells|

Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

25 11, 2020

Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK

2022-02-07T13:30:35+00:00November 25th, 2020|animal-free, News, organoid news|

Qkine, Manchester BIOGEL and Cellesce have been awarded Innovate UK Sustainable Innovation Funding to develop fully synthetic, chemically-defined three-dimensional (3D) scaffolds to enable manufacture scale up and improve reproducibility of patient-derived organoids.

Go to Top